Charles D Lopez
OHSU Knight Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charles D Lopez as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:05 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07089940 · OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaOHSU Knight Cancer Institute · recruiting · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 · principal investigator
- Ph2NCT06630325 · A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerOHSU Knight Cancer Institute · terminated · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma · principal investigator
- Ph2NCT06398587 · Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal AdenocarcinomaOHSU Knight Cancer Institute · withdrawn · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 · principal investigator
- Ph1NCT05034627 · Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic CancerOHSU Knight Cancer Institute · completed · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 · principal investigator
- Ph2NCT04539808 · NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic CancerOHSU Knight Cancer Institute · active not recruiting · Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8 · principal investigator
- Ph1NCT04104139 · TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal CancerOHSU Knight Cancer Institute · completed · Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8 · principal investigator
- Early Ph1NCT04005690 · Targeted Pathway Inhibition in Patients With Pancreatic CancerOHSU Knight Cancer Institute · recruiting · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:05 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.J Clin Oncol · 2023135 citationsRCR 12.5
- 100 citationsRCR 5.0
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.J Immunother Cancer · 202087 citationsRCR 3.2
- 59 citationsRCR 4.7
- 49 citationsRCR 5.5
- Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.Am J Clin Oncol · 201141 citationsRCR 0.9
- A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.Am J Clin Oncol · 201820 citationsRCR 0.8
- 15 citationsRCR 1.1
- Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.J Immunother Cancer · 20239 citationsRCR 0.6
- 7 citationsRCR 0.3